Surrozen, Inc. SRZN

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
52/100
Moderate

Ranked against 712 peers in Biotechnology

About Surrozen, Inc.

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular … Full SRZN analysis →

Key strengths

  • ROIC Sustainably Above Peers ROIC at 88.8th percentile exceeds peers and WACC, demonstrating superior capital allocation.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.77), providing operational cushion.

Key risks

  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.00), suggesting weak customer stickiness.
  • Inconsistent Cash Generation Cash generation is inconsistent (score 0.41), indicating operational challenges.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
44
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where SRZN ranks in Biotechnology

Surrozen, Inc. ranks #214 of 713 scored companies in Biotechnology by moat score — the top 30%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
210 X4 Pharmaceuticals, Inc. XFOR 52/100 Moderate
211 Pulmatrix, Inc. PULM 52/100 Moderate
212 FibroGen, Inc FGEN 52/100 Moderate
213 Edesa Biotech, Inc. EDSA 52/100 Moderate
214 Surrozen, Inc. SRZN 52/100 Moderate
215 Moolec Science SA MLEC 52/100 Moderate
216 Moolec Science SA Warrant MLECW 52/100 Moderate
217 Surrozen, Inc. Warrant SRZNW 52/100 Moderate
218 Verrica Pharmaceuticals Inc. VRCA 52/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How SRZN scores on the Corporate Default defenses

Pricing Power

Score 44 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 38 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 41 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 68 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 61 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 51 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding SRZN's moat

What is Surrozen, Inc.'s moat score?

Surrozen, Inc. (SRZN) scores 52 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #214 of 713 scored companies in Biotechnology, the top 30%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (68/100) and its weakest is Cost Advantage (38/100).

How does Surrozen, Inc. compare with other Biotechnology companies?

Surrozen, Inc. ranks #214 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Edesa Biotech, Inc. (EDSA) at 52 just above it and Moolec Science SA (MLEC) at 52 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Surrozen, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Surrozen, Inc.?

The Corporate Default template measures 6 defenses, and SRZN scores: Pricing Power (44), Cost Advantage (38), Customer Stickiness (41), Capital Efficiency (68), Resilience (61), Scale & Market Position (51). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000